Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39419061/
Bristol-Myers Squibb, Spanish Ministry of Science, Instituto de Salud Carlos III, European Union.
The NADIM trial shows perioperative chemoimmunotherapy with nivolumab yields durable survival benefits in resectable stage IIIA NSCLC, with 5-year overall survival of 69% and manageable long-term toxicity.
Advances in molecular pathology and therapy of non-small cell lung cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40517166/
Over the past two decades, non-small cell lung cancer (NSCLC) has witnessed encouraging advancements in basic and clinical research. However, substantial unmet needs remain for patients worldwide, as drug resistance...
This review summarizes advancements in NSCLC research, covering molecular pathology, therapeutic targets, drugs, resistance mechanisms, and AI-driven biomarker-based strategies, highlighting translational potential for reshaping treatments and developing innovative targeted therapies.
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39995659/
Over the past decades, significant progress has been made in the understanding of non-small cell lung cancer (NSCLC) biology and tumor progression mechanisms, resulting in the development of novel strategies...
Progress in NSCLC therapy includes TKIs and ICIs, but resistance and toxicity persist. The tumor microenvironment hinders CAR-T therapy, necessitating strategies targeting immunosuppression, antigen escape, and combination with checkpoint inhibitors.
Treatment of non-small cell lung cancer with RET rearrangements - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40171987/
Aberrant activation of the RET oncogene by mutations or gene fusions drives various malignancies, including 1%-2% of all non-small cell lung cancers (NSCLCs) that harbor RET gene fusions. Initial attempts...
RET fusions drive NSCLC in 1–2% of cases. Selective inhibitors, such as selpercatinib and pralsetinib, outperform older therapies, with selpercatinib demonstrating phase 3 superiority, which guides resistance management and informs next-generation drug development.
Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39461773/
After longer follow-up, first-line tislelizumab plus chemotherapy continued to demonstrate a manageable safety profile and a favorable PFS benefit over chemotherapy alone in patients with advanced/metastatic nsq-NSCLC.
Final analysis of RATIONALE-304 shows tislelizumab plus chemotherapy improved PFS versus chemotherapy alone in advanced nsq-NSCLC, with manageable safety, OS benefit after crossover adjustment, and consistent tolerability.